Mental and Behavioral Health

Nina Vadiei, PharmD, BCPP, discusses some of the challenges she faces working with forensic patients who have been charged with a crime and have severe mental illness.

Continued methylphenidate or atomoxetine use may be safe, but additional studies are needed.

The drug is also approved to treat schizophrenia and bipolar depression.

Researchers addressed the gut-first hypothesis of Parkinson disease by identifying how mucosal damage impacts risk of development.

Normalizing conversations around mental health in older adult populations can improve outcomes.

A conversation with Rakesh Jain, MD, MPH, clinical professor in the Department of Psychiatry at Texas Tech University School of Medicine.

Pharmacist management of chronic conditions can lead to improved patient outcomes.

The partnership will provide tools to address both patient and pharmacist well-being amid the current mental health crisis.

The COVID-19 pandemic negatively impacted mental health in young people, and additional targeted mental health resources are needed.

The once-daily, extended release, oral suspension medication was approved by the FDA in May 2024.

The approval of xanomeline and trospium chloride (Cobenfy) from Bristol Myers Squibb represents a “transformative moment in the treatment of schizophrenia.”

Study findings raise concern about increased pain and disability, poorer pain self-management, and impaired quality of life during adolescence that can continue into young adulthood.

Researchers conducted a meta-analysis and systematic review to determine the efficacy of using antidepressants to treat older adults for knee osteoarthritis pain.

Researchers conducted a meta-analysis detailing previous patient outcomes in response to visual art therapy interventions.

Researchers analyzed a co-developed pharmacy-based intervention for individuals who have experienced domestic abuse or suicidal ideation.

DaylightRX from Big Health is a digital formulation of cognitive behavioral therapy and is available by prescription only.

As research continues to uncover the potential benefits of psilocybin, pharmacists and other clinicians have an essential role in bridging ancient wisdom with contemporary science.

Rejoyn, developed by Otsuka Pharmaceutical and Click Therapeutics, is only accessible with a prescription from a health care provider.

The agency said it could not approve the new drug application based on the submitted data and requested an additional Phase 3 trial to “further study the safety and efficacy” of the therapy.

Researchers aimed to address the association of all-cause dementia risk and 3 separate chronicities of anxiety.

Patients with childhood type 1 diabetes were more likely to develop substance use disorders, mood disorders, anxiety disorders, and behavioral syndromes.

Farron Dozier, former sergeant first class in the US Army, sat down with Drug Topics on a recent episode of Over the Counter to discuss his experience with PTSD.

Researchers aimed to address the extent of stigmatization’s effect on the mental health of adolescents with chronic skin disorders.

“They may not understand. But I tell people, ‘I don't want you to understand me.’ I don't understand me. But if you can relate to me, then that furthers our conversation—the relatedness,” said Farron Dozier on his experience with PTSD.

A former sergeant first class in the US Army discussed PTSD in an exclusive interview with Drug Topics.

Sam Clark, MD, PhD, founder and CEO of Terran Biosciences, discusses what the future looks like for psychedelic treatments.

Two phase 3 clinical trials form the basis of a supplemental New Drug Application for this indication.

The CDC released an alert encouraging pharmacists and providers to counsel patients around the harms of illegal stimulant medications.

“The more we share our experiences and stories and work together as a profession, the more we can come together to support each other and form solutions,” said Joanna Lewis, PharmD, MBA, wellness writer and advocate, on overcoming burnout in the pharmacy.

The Psychopharmacologic Drugs Advisory Committee voted 10-1 that the benefits of MDMA do not outweigh its potential risks.